A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of
targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with
recurrent and/or persistent endometrial cancer. The main protocol provides a platform for
genomic screening with homogeneous basic eligibility criteria in order to direct study
subjects into biomarker-matched study cohorts consisting of testing targeted agents with
atezolizumab.